A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07429721
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma (MM)
Interventions
DRUG:
QI-019A Injection
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology